

# A PIONEER IN HEALTHCARE

We have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.

# Roche

## SALSS CONTACT

**Amy VanBuskirk**  
CEO, Roche AB

amy.vanbuskirk@roche.com  
+ 46 (0) 8 726 12 00

**Roche AB**  
Arvid Tydén's älle 7  
171 69 Solna  
Sweden



Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics, with headquarters located in Basel. Roche is the third-largest pharma company worldwide and the world's number 1 in biotech, with 17 biopharmaceuticals on the market. Over half of the compounds in our product pipeline are biopharmaceuticals, enabling us to deliver better-targeted therapies.

## OUR PRODUCTS & SERVICES

With one of the strongest pipelines in the industry, Roche Neuroscience is developing medicines for a range of serious neurological diseases, including multiple sclerosis, Alzheimer's disease, autism, spinal muscular atrophy, depression and Parkinson's disease.

- Spinal muscular atrophy is a rare genetic neuromuscular condition, affecting approximately 1 in 6,000 babies born worldwide each year.
- Alzheimer's disease, a progressive, fatal brain disease and the most common cause of dementia. 46 million people worldwide are living with dementia.
- MS is a disease of the central nervous system, estimated to affect 2.3 million people worldwide.

We are investing in informatics and big data-driven tools to help patients, healthcare professionals and authorities to make the most educated decisions - see Foundation Medicine and Flatiron Health.

## WHAT MAKES US UNIQUE

We are guided by our purpose: Doing now what patients need next. Our company has a 120-year history of advancing the field of medicine and bringing novel treatments and diagnostics to patients. The patient is and will remain at the core of what we do, the reason we come to work every day.

In our pursuit of excellence in science, our distinctiveness rests on four key elements: an exceptionally broad and deep understanding of molecular biology, the seamless integration of our pharmaceuticals and diagnostics capabilities, a diversity of approaches to maximise innovation, and a long-term orientation. We will continue to concentrate our energies entirely on prescription medicines and in vitro diagnostics, rather than diversify.

## WHY YOU SHOULD MEET US

Our autonomous research and development centres and alliances with over 200 external partners foster diversity and agility. Our global geographical scale and reach enables us to bring our diagnostics and medicines quickly to people who need them.

## KEY TEAM

**Amy VanBuskirk, MBA**

- CEO
- Amy joined Roche/Genentech in 2002 and is known for her ability to provide strategic focus, her passion for tackling complex problems and her people-focused leadership

**Björn Arvidsson, MSc, PhD**

- Head of Policy and Communications
- Björn has been with Roche for a decade and was formerly with the Swedish Defence Research Agency

